Chevy Chase Trust Holdings LLC Sells 8,557 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Chevy Chase Trust Holdings LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 221,210 shares of the biopharmaceutical company’s stock after selling 8,557 shares during the quarter. Chevy Chase Trust Holdings LLC owned approximately 0.20% of Regeneron Pharmaceuticals worth $140,298,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Capital International Investors raised its stake in shares of Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after acquiring an additional 155,369 shares during the last quarter. Dodge & Cox boosted its stake in shares of Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock worth $1,653,543,000 after acquiring an additional 9,381 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after buying an additional 810,144 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock valued at $1,456,864,000 after buying an additional 149,124 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Bank of America lowered their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a report on Thursday, April 17th. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 22nd. Guggenheim reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Finally, UBS Group lowered their price target on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating for the company in a report on Thursday, June 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $836.48.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $511.92 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The firm has a market capitalization of $55.27 billion, a PE ratio of 13.03, a price-to-earnings-growth ratio of 1.87 and a beta of 0.31. The stock’s 50-day simple moving average is $557.15 and its 200-day simple moving average is $638.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same period last year, the business posted $9.55 EPS. Regeneron Pharmaceuticals’s revenue was down 3.7% on a year-over-year basis. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.69%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.